Apollomics received a Nasdaq notice for failing to maintain the $35 million minimum Market Value of Listed Securities after 30 consecutive days, triggering a compliance period that expires December 15, 2026. It also terminated its $3.8 million collaboration with Launxp, regaining global rights to vebreltinib outside Mainland China and Macau.
Apollomics received a Nasdaq notice on June 18, 2026, for failure to maintain a $35 million minimum Market Value of Listed Securities after 30 consecutive days from May 6 to June 17, triggering a 180-day compliance window to restore MVLS or face delisting.
Effective June 11, Apollomics terminated its collaboration with Launxp for nonpayment of the remaining $3.8 million upfront balance plus interest, initiating a 30-day negotiation followed by escalation to executive-level dispute resolution to recover funds and defend termination rights.
With licenses to vebreltinib automatically reverting from Launxp, Apollomics now holds all development and commercialization rights for its c-Met inhibitor outside Mainland China and Macau, consolidating strategic control across the U.S., Europe and broader Asia-Pacific region.
